21 C.F.R. § 20.55

Indexing trade secrets and confidential commercial or financial information

Read at: eCFRecfr.gov CornellLII GovInfogovinfo.gov CasesGoogle Scholar

Whenever the Food and Drug Administration denies a request for a record or portion thereof on the grounds that the record or portion thereof is exempt from public disclosure as trade secret or confidential commercial or financial data and information under § 20.61, and the person requesting the record subsequently contests the denial in the courts, the Food and Drug Administration will so inform the person affected, i.e., the person who submitted the record, and will require that such person intervene to defend the exempt status of the record. If a court requires the Food and Drug Administration to itemize and index such records, the Food and Drug Administration will so inform the person affected and will require that such person undertake the itemization and indexing of the records. If the affected person fails to intervene to defend the exempt status of the records and to itemize and index the disputed records, the Food and Drug Administration will take this failure into consideration in deciding whether that person has waived such exemption so as to require the Food and Drug Administration to promptly make the records available for public disclosure.

[42 FR 15616, Mar. 22, 1977, as amended at 59 FR 535, Jan. 5, 1994. Redesignated at 68 FR 25286, May 12, 2003]
Notes of Decisions
Cited in 1 case, 2004–2004 · leading case: Appleton v. Food & Drug Admin., 310 F. Supp. 2d 194 (D.D.C. 2004).
Appleton v. Food & Drug Admin., 310 F. Supp. 2d 194 (D.D.C. 2004). · cites it 2× “Compare Joint Status Report at 5-6 (listing the information the plaintiff seeks) and 21 C.F.R. § 20.55 (requiring that persons whose FDA records include trade secrets or confidential information intervene to defend the exempt status of the records or else risk FDA’s public…”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.